Early Access

10-QPeriod: Q2 FY2016

SYNOPSYS INC Quarterly Report for Q2 Ended Apr 30, 2016

Filed May 24, 2016For Securities:SNPS

Summary

Synopsys Inc. reported solid financial results for the quarter and six months ended April 30, 2016, demonstrating continued revenue growth and profitability. Total revenue increased by 9% year-over-year for the quarter and 7% for the six-month period, primarily driven by an increase in time-based license revenue, which continues to represent the majority of the company's revenue. The company's strong operational performance is supported by its robust time-based revenue model, which provides a predictable revenue stream. Synopsys also maintained a healthy cash position, with cash, cash equivalents, and short-term investments totaling $959.9 million. The company continued to execute on its strategic objectives, including investments in research and development and acquisitions, while also actively managing its capital through stock repurchases.

Financial Statements
Beta
Revenue$605.00M
Cost of Revenue$131.63M
Gross Profit$473.38M
R&D Expenses$216.17M
Operating Expenses$386.57M
Operating Income$86.81M
Interest Expense$848K
Net Income$69.38M
EPS (Basic)$0.46
EPS (Diluted)$0.45
Shares Outstanding (Basic)152.25M
Shares Outstanding (Diluted)154.54M

Key Highlights

  • 1Total revenue increased by 9% to $605.0 million for the three months ended April 30, 2016, compared to $557.2 million in the prior year period.
  • 2Time-based license revenue, the company's primary revenue stream, grew 8% to $484.2 million for the quarter.
  • 3Gross margin remained strong at 78% for the quarter, indicating effective cost management.
  • 4Research and development expenses increased by 15% to $216.2 million, reflecting continued investment in innovation.
  • 5Net income increased by 25% to $69.4 million for the quarter, showcasing improved profitability.
  • 6The company maintained a healthy liquidity position with $959.9 million in cash, cash equivalents, and short-term investments as of April 30, 2016.
  • 7Synopsys repurchased approximately $20.0 million of its common stock during the quarter.

Frequently Asked Questions